These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12071779)

  • 21. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
    Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
    Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescription-event monitoring of 10,401 patients treated with fluvoxamine.
    Edwards JG; Inman WH; Wilton L; Pearce GL
    Br J Psychiatry; 1994 Mar; 164(3):387-95. PubMed ID: 7993416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.
    Perrio MJ; Wilton LV; Shakir SA
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):969-78. PubMed ID: 17476703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription-event monitoring: methodology and recent progress.
    Rawson NS; Pearce GL; Inman WH
    J Clin Epidemiol; 1990; 43(5):509-22. PubMed ID: 2324790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription-event monitoring and reporting of adverse drug reactions.
    Heeley E; Riley J; Layton D; Wilton LV; Shakir SA
    Lancet; 2001 Dec; 358(9296):1872-3. PubMed ID: 11741629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM).
    Yokotsuka M; Aoyama M; Kubota K
    Int J Med Inform; 2000 Jul; 57(2-3):139-53. PubMed ID: 10961570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety related drug-labelling changes: findings from two data mining algorithms.
    Hauben M; Reich L
    Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A brief primer on automated signal detection.
    Hauben M
    Ann Pharmacother; 2003; 37(7-8):1117-23. PubMed ID: 12841826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paediatric post-marketing pharmacovigilance: comparison of the adverse event profile of vigabatrin prescribed to children and adults.
    Aurich-Barrera B; Wilton L; Brown D; Shakir S
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):608-18. PubMed ID: 21351182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A qualitative approach to signal mining in pharmacovigilance using formal concept analysis.
    Lillo-Le Louët A; Toussaint Y; Villerd J
    Stud Health Technol Inform; 2010; 160(Pt 2):969-73. PubMed ID: 20841828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of stratification on adverse drug reaction surveillance.
    Hopstadius J; Norén GN; Bate A; Edwards IR
    Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription-event and other forms of epidemiological monitoring of side-effects in the UK.
    Dunn N; Mann RD
    Clin Exp Allergy; 1999 Jul; 29 Suppl 3():217-39. PubMed ID: 10444241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
    Layton D; Harris S; Wilton LV; Shakir SA
    J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescription-event monitoring. A preliminary study of benoxaprofen and fenbufen.
    Inman WH
    Acta Med Scand Suppl; 1984; 683():119-26. PubMed ID: 6234753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.